Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2416964 plus Pembrolizumab in Advanced Solid Tumors
NCT04999202Phase 1Terminated
- Sponsor
- Bayer
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 4
01
Overview
Phase 1, open-label trial of bay2416964 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Bayer. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Severity of Treatment-Emergent Adverse Events and 1 more. Started Aug 2021; status: terminated.
02
Drugs
bay2416964
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04999202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999202.